This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/chemspider/
n20http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/patent/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/kegg-compound/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/bindingdb/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00949/identifier/kegg-drug/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00949
rdf:type
n3:Drug
n3:description
Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
n3:dosage
n4:271B4094-363D-11E5-9242-09173F13E4C5 n4:271B4095-363D-11E5-9242-09173F13E4C5 n4:271B4093-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991 Nov;41(11):1785-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1944909
n3:group
approved
n3:halfLife
20-23 hours
n3:indication
For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
n3:manufacturer
n6:271B408F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00949 n20:DB00949
dcterms:title
Felbamate
adms:identifier
n8:3331 n12:46506375 n13:0037-0430-01 n14:PA449590 n21:C07501 n22:D00536 n23:3214 n24:DB00949 n25:50240678 n27:4995 n29:Felbamate
n3:mechanismOfAction
The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. <i>In vitro</i> receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.
n3:packager
n6:271B408D-363D-11E5-9242-09173F13E4C5 n6:271B408E-363D-11E5-9242-09173F13E4C5 n6:271B408C-363D-11E5-9242-09173F13E4C5 n6:271B408B-363D-11E5-9242-09173F13E4C5
n3:patent
n11:4978680
n3:synonym
Felbamatum Carbamic acid 2-phenyltrimethylene ester Felbamato Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester Felbamate 2-Phenyl-1,3-propanediol dicarbamate
n3:toxicity
LD<sub>50</sub>=5000 mg/kg (Orally in rats)
n3:volumeOfDistribution
* 756±82 mL/kg
n3:foodInteraction
Taking it after a meal may reduce the incidence of adverse effects.
n3:proteinBinding
20-36%
foaf:page
n16:felbamate.htm n26:felbamate.html
n3:IUPAC-Name
n5:271B409A-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B40A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B409F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B409C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B409D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B409E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4098-363D-11E5-9242-09173F13E4C5 n5:271B40AF-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4096-363D-11E5-9242-09173F13E4C5 n5:271B4099-363D-11E5-9242-09173F13E4C5 n5:271B40B1-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4097-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N03AX10
n3:H-Bond-Acceptor-Count
n5:271B40A6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B40A7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B40A1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B40A2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B40A4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B40A3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B40A5-363D-11E5-9242-09173F13E4C5
n3:absorption
>90%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
25451-15-4
n3:category
n3:clearance
* 26 +/- 3 mL/hr/kg [single 1200 mg dose] * 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
n3:containedIn
n19:271B4091-363D-11E5-9242-09173F13E4C5 n19:271B4092-363D-11E5-9242-09173F13E4C5 n19:271B4090-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B40AB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B40AD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B40AE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B40B0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B40AA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B40A9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B40AC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B409B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B40A8-363D-11E5-9242-09173F13E4C5